Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2007 1
2008 5
2009 3
2010 2
2011 3
2012 2
2013 2
2014 6
2015 4
2016 7
2017 8
2018 12
2019 7
2020 7
2021 4
2022 4
2023 5
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

73 results

Results by year

Filters applied: . Clear all
Page 1
Impact of Thrombolytic Therapy on the Long-Term Outcome of Intermediate-Risk Pulmonary Embolism.
Konstantinides SV, Vicaut E, Danays T, Becattini C, Bertoletti L, Beyer-Westendorf J, Bouvaist H, Couturaud F, Dellas C, Duerschmied D, Empen K, Ferrari E, Galiè N, Jiménez D, Kostrubiec M, Kozak M, Kupatt C, Lang IM, Lankeit M, Meneveau N, Palazzini M, Pruszczyk P, Rugolotto M, Salvi A, Sanchez O, Schellong S, Sobkowicz B, Meyer G. Konstantinides SV, et al. Among authors: lang im. J Am Coll Cardiol. 2017 Mar 28;69(12):1536-1544. doi: 10.1016/j.jacc.2016.12.039. J Am Coll Cardiol. 2017. PMID: 28335835 Free article. Clinical Trial.
BACKGROUND: The long-term effect of thrombolytic treatment of pulmonary embolism (PE) is unknown. ...RESULTS: Long-term (median 37.8 months) survival was assessed in 353 of 359 (98.3%) patients in the thrombolysis arm and in 343 of 350 (98.0%) in the placebo arm. .. …
BACKGROUND: The long-term effect of thrombolytic treatment of pulmonary embolism (PE) is unknown. ...RESULTS: Long-term (media …
Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.
Galiè N, Barberà JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, Peacock AJ, Simonneau G, Vachiery JL, Grünig E, Oudiz RJ, Vonk-Noordegraaf A, White RJ, Blair C, Gillies H, Miller KL, Harris JH, Langley J, Rubin LJ; AMBITION Investigators. Galiè N, et al. N Engl J Med. 2015 Aug 27;373(9):834-44. doi: 10.1056/NEJMoa1413687. N Engl J Med. 2015. PMID: 26308684 Free article. Clinical Trial.
BACKGROUND: Data on the effect of initial combination therapy with ambrisentan and tadalafil on long-term outcomes in patients with pulmonary arterial hypertension are scarce. ...The primary end point in a time-to-event analysis was the first event of clinical failure, whi …
BACKGROUND: Data on the effect of initial combination therapy with ambrisentan and tadalafil on long-term outcomes in patients with p …
Long-Term Survival, Safety and Tolerability with Selexipag in Patients with Pulmonary Arterial Hypertension: Results from GRIPHON and its Open-Label Extension.
Galiè N, Gaine S, Channick R, Coghlan JG, Hoeper MM, Lang IM, McLaughlin VV, Lassen C, Rubin LJ, Hsu Schmitz SF, Sitbon O, Tapson VF, Chin KM. Galiè N, et al. Among authors: lang im. Adv Ther. 2022 Jan;39(1):796-810. doi: 10.1007/s12325-021-01898-1. Epub 2021 Oct 30. Adv Ther. 2022. PMID: 34727317 Free PMC article. Clinical Trial.
The ongoing open-label extension study (GRIPHON OL) collects further data on long-term safety, tolerability, and survival of PAH patients treated with selexipag. ...A large proportion of the population was receiving background therapy at selexipag initiation, providing fur …
The ongoing open-label extension study (GRIPHON OL) collects further data on long-term safety, tolerability, and survival of PAH pati …
Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension. A Double-Blind Placebo-controlled Clinical Trial.
White RJ, Jerjes-Sanchez C, Bohns Meyer GM, Pulido T, Sepulveda P, Wang KY, Grünig E, Hiremath S, Yu Z, Gangcheng Z, Yip WLJ, Zhang S, Khan A, Deng CQ, Grover R, Tapson VF; FREEDOM-EV Investigators. White RJ, et al. Am J Respir Crit Care Med. 2020 Mar 15;201(6):707-717. doi: 10.1164/rccm.201908-1640OC. Am J Respir Crit Care Med. 2020. PMID: 31765604 Free PMC article. Clinical Trial.
The primary endpoint was the time to first adjudicated clinical worsening event: death; hospitalization due to worsening PAH; initiation of inhaled or parenteral prostacyclin therapy; disease progression; or unsatisfactory long-term clinical response.Measurements and Main …
The primary endpoint was the time to first adjudicated clinical worsening event: death; hospitalization due to worsening PAH; initiation of …
Chronic thromboembolic pulmonary hypertension: realising the potential of multimodal management.
Delcroix M, de Perrot M, Jaïs X, Jenkins DP, Lang IM, Matsubara H, Meijboom LJ, Quarck R, Simonneau G, Wiedenroth CB, Kim NH. Delcroix M, et al. Among authors: lang im. Lancet Respir Med. 2023 Sep;11(9):836-850. doi: 10.1016/S2213-2600(23)00292-8. Epub 2023 Aug 14. Lancet Respir Med. 2023. PMID: 37591299 Review.
Further work is needed to optimise the use and combination of multimodal therapeutic options in CTEPH to improve long-term outcomes for patients....
Further work is needed to optimise the use and combination of multimodal therapeutic options in CTEPH to improve long-term outcomes f …
Riociguat and the right ventricle in pulmonary arterial hypertension and chronic thromboembolic pulmonary hypertension.
Benza RL, Langleben D, Hemnes AR, Vonk Noordegraaf A, Rosenkranz S, Thenappan T, Hassoun PM, Preston IR, Ghio S, Badagliacca R, Vizza CD, Lang IM, Meier C, Grünig E. Benza RL, et al. Among authors: lang im. Eur Respir Rev. 2022 Oct 5;31(166):220061. doi: 10.1183/16000617.0061-2022. Print 2022 Dec 31. Eur Respir Rev. 2022. PMID: 36198418 Free PMC article. Review.
Right ventricular dysfunction, hypertrophy and maladaptive remodelling are consequences of increased right ventricular (RV) afterload in PAH and CTEPH and are indicative of long-term outcomes. Because RV failure is the main cause of morbidity and mortality in PAH and CTEPH …
Right ventricular dysfunction, hypertrophy and maladaptive remodelling are consequences of increased right ventricular (RV) afterload in PAH …
Left Ventricular Filling Pressure in Chronic Thromboembolic Pulmonary Hypertension.
Gerges C, Pistritto AM, Gerges M, Friewald R, Hartig V, Hofbauer TM, Reil B, Engel L, Dannenberg V, Kastl SP, Skoro-Sajer N, Moser B, Taghavi S, Klepetko W, Lang IM. Gerges C, et al. Among authors: lang im. J Am Coll Cardiol. 2023 Feb 21;81(7):653-664. doi: 10.1016/j.jacc.2022.11.049. J Am Coll Cardiol. 2023. PMID: 36792280 Free article.
Two cutoffs were applied to identify patients with elevated LVFP: 1) for the primary analysis mPAWP and/or LVEDP >15 mm Hg, as recommended by the current pulmonary hypertension guidelines; and 2) for the secondary analysis mPAWP and/or LVEDP >11 mm Hg, representing the uppe …
Two cutoffs were applied to identify patients with elevated LVFP: 1) for the primary analysis mPAWP and/or LVEDP >15 mm Hg, as recommende …
Early selexipag initiation and long-term outcomes: insights from randomised controlled trials in pulmonary arterial hypertension.
Coghlan JG, Gaine S, Channick R, Chin KM, du Roure C, Gibbs JSR, Hoeper MM, Lang IM, Mathai SC, McLaughlin VV, Mitchell L, Simonneau G, Sitbon O, Tapson VF, Galiè N. Coghlan JG, et al. Among authors: lang im. ERJ Open Res. 2023 Jan 16;9(1):00456-2022. doi: 10.1183/23120541.00456-2022. eCollection 2023 Jan. ERJ Open Res. 2023. PMID: 36687361 Free PMC article.
Further understanding of when to initiate therapies in pulmonary arterial hypertension (PAH) is important to improve long-term outcomes. Post hoc analyses of GRIPHON (NCT01106014) and exploratory analyses of TRITON (NCT02558231) suggested benefit of early selexipag initiat …
Further understanding of when to initiate therapies in pulmonary arterial hypertension (PAH) is important to improve long-term outcom …
Pulmonary hypertension in chronic heart failure.
Bonderman D, Martischnig AM, Moertl D, Lang IM. Bonderman D, et al. Among authors: lang im. Int J Clin Pract Suppl. 2009 Mar;(161):4-10. doi: 10.1111/j.1742-1241.2008.01950.x. Int J Clin Pract Suppl. 2009. PMID: 19178599 Review.
Moreover, apart from single-centre observations no large-scale trial to date has demonstrated a long-term benefit from pulmonary vasoactive drugs. As a result, there are currently no consensus recommendations for the treatment of PH in the presence of CHF. ...
Moreover, apart from single-centre observations no large-scale trial to date has demonstrated a long-term benefit from pulmonary vaso …
Evolution of secondary mitral regurgitation.
Bartko PE, Pavo N, Pérez-Serradilla A, Arfsten H, Neuhold S, Wurm R, Lang IM, Strunk G, Dal-Bianco JP, Levine RA, Hülsmann M, Goliasch G. Bartko PE, et al. Among authors: lang im. Eur Heart J Cardiovasc Imaging. 2018 Jun 1;19(6):622-629. doi: 10.1093/ehjci/jey023. Eur Heart J Cardiovasc Imaging. 2018. PMID: 29534164 Free PMC article.
METHODS AND RESULTS: We prospectively enrolled 249 patients with chronic heart failure and reduced ejection fraction receiving GDT in this long-term observational study. Of patients with non-severe MR at baseline 81% remained stable whereas 19% had progressive MR. ...
METHODS AND RESULTS: We prospectively enrolled 249 patients with chronic heart failure and reduced ejection fraction receiving GDT in this l …
73 results